Ozempic
semaglutide
- Strength
- .68 mg/mL
- Form
- Injection, Solution
- Class
- GLP-1 Receptor Agonist
Novo Nordisk Pharmaceutical Industries, LP
semaglutide
Listed by Novo Nordisk Pharmaceutical Industries, LP
| Dosage form | Injection, Solution |
|---|---|
| Route | Subcutaneous |
| Drug class | GLP-1 Receptor Agonist |
| Approval route | NDA — original brand approval |
| NDC code | 0169-4572 |
| FDA application | NDA215256 |
| Package sizes listed | 1 |
| Marketed since | June 2021 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
semaglutide
Novo Nordisk Pharmaceutical Industries, LP
semaglutide
Novo Nordisk Pharmaceutical Industries, LP
oral semaglutide
Novo Nordisk Pharmaceutical Industries, LP
semaglutide
A-S Medication Solutions
semaglutide
Novo Nordisk Pharmaceutical Industries, LP
semaglutide
A-S Medication Solutions
semaglutide
A-S Medication Solutions
oral semaglutide
Novo Nordisk Pharmaceutical Industries, LP
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.